Converteo has unveiled a new offering aimed at enhancing AI capabilities within the Pharma and Life Sciences sectors, addressing the need for faster innovation and compliance in a challenging regulatory environment.
The new services, launched across multiple markets including France, Italy, Spain, the United States, and Canada, are designed to help healthcare organizations automate intricate workflows while implementing secure AI solutions. This initiative is a response to the pharmaceutical industry's increasing investment in AI, which has surged since 2024. Companies in this sector face mounting regulatory pressures and the need for improved operational efficiency, making agile and resilient solutions essential for long-term success.
Converteo's offering draws on nearly two decades of experience in deploying production-grade AI systems, particularly focusing on Data, Agentic, and Generative AI platforms. The goal is to facilitate quick deployment of enterprise agent systems that can deliver measurable results within weeks. This initiative is bolstered by a strategic partnership with Google, ensuring that AI implementations are both secure and high-performing.
To spearhead this global initiative, Converteo has appointed Vanessa de Langsdorff as Partner and Global Lead for Pharma & Life Sciences. With over 15 years of experience in consulting and digital transformation in regulated industries, she is well-equipped to guide life sciences organizations in their data and AI transformation efforts. De Langsdorff emphasizes the importance of speed, data accuracy, and trust in AI tools, highlighting Converteo's unique position to help companies efficiently navigate regulatory requirements while accelerating the delivery of therapies to patients.